Celyad Announces February and March 2020 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the company plans to participate at the following conferences in February and March 2020:

9th Annual SVB Leerink Global Healthcare Conference
Date: Presentation time:  Location:  Webcast:	Tuesday, February 25, 2020 3:30 p.m. ET  New York, New York A live and archived webcast of the presentation will be available in the Events & Webcasts section of the Celyad website
3rd Annual CAR-TCR Summit Europe
Date: Time: Location:	Wednesday, February 26, 2020 12:30 p.m. GMT London, United Kingdom
27th International Molecular Med Tri-Conference
Date:  Presentation Time:  Location:	Wednesday, March 4, 2020 2:35 p.m. PT San Francisco, California
Cambridge Healthtech Institute’s 5th Annual Immuno-Oncology Summit Europe 2020
Date: Presentation time: Location:	Wednesday, March 11, 2020 9:05 a.m. GMT  London, United Kingdom
BioCapital Europe 2020
Date: Presentation time: Location:	Thursday, March 12, 2020 3:50 p.m. CET  Amsterdam, Netherlands
VFB Congress Happening
Date:  Presentation time: Location:	Saturday, March 28, 2020 1:40 p.m. CET Antwerp, Belgium

About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. Celyad has received funding from the Walloon Region (Belgium) to support the advancement of its CAR-T cell therapy programs.